Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022

This poster explores the use of electronic health records (EHR) to identify exposures to unapproved cannabis-derived products (CDPs), including cannabidiol (CBD), as part of active safety surveillance efforts in the United States. It was presented at the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.